(Q24243149)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

1 reference

title

Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

0 references

metabolic dysfunction–associated steatotic liver disease

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

R Orlando

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

S Orando

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

F Lirussi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

24 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

CD005160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Hepatic steatosis in obese patients: clinical aspects and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Update on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

7 January 2021

inferred from DOI database lookup

Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

7 January 2021

inferred from DOI database lookup

Nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005160.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD005160.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253541%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference